# Hans‐Peter Gerber

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hans-peter-gerber/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,119 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 58 |
| i10-index | 81 |
| Last Known Institution | Sutro Biopharma (United States) |
| OpenAlex ID | https://openalex.org/A5052067361 |
| ORCID iD | https://orcid.org/0000-0002-0741-9328 |
| Works | 240 |

## Researcher papers

- [Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments](https://scholariq.org/papers/tumor-cells-chronically-treated-with-a-trastuzumab-maytansinoid-antibody-drug/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Angiogenesis and VEGF in Cancer](https://scholariq.org/topics/angiogenesis-and-vegf-in-cancer/)
- [Cell Adhesion Molecules Research](https://scholariq.org/topics/cell-adhesion-molecules-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [Sutro Biopharma (United States)](https://scholariq.org/institutions/sutro-biopharma-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.